POINT Biopharma Global Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Indianapolis, IN
SEC filing record 1 source field available
Fiscal year end
31 December
POINT Biopharma Global Inc. has filed 285 SEC EDGAR filings since 14 May 2020

SEC filing history

Showing 126-150 of 285 matching filings.

Per page
25
Current page
6
4

OWNERSHIP DOCUMENT

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

OWNERSHIP DOCUMENT

Filing date
31 Mar 2022
Reporting date
29 Mar 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
424B3 File 333-258325

424B3

Filing date
31 Mar 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-258325

EFFECT filing

Filing date
28 Mar 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
5/A

OWNERSHIP DOCUMENT

Filing date
17 Mar 2022
Reporting date
31 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
424B3 File 333-258325

424B3

Filing date
25 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
424B3 File 333-258325

424B3

Filing date
15 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

SC 13G/A

Filing date
15 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
5

OWNERSHIP DOCUMENT

Filing date
14 Feb 2022
Reporting date
31 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

SC 13G/A

Filing date
14 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

SC 13G/A filing

Filing date
14 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

PNT AS OF 12/31/2021

Filing date
14 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

AMENDMENT NO. 2 TO THE SCHEDULE 13G

Filing date
14 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

SC 13G/A filing

Filing date
11 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

POINT BIOPHARMA GLOBAL INC.

Filing date
11 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4/A

OWNERSHIP DOCUMENT

Filing date
08 Feb 2022
Reporting date
30 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

SC 13G/A filing

Filing date
07 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-91575

SEC SCHEDULE 13G

Filing date
04 Feb 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
10 Dec 2021
Reporting date
09 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .